(OSCR) Oscar Health - Overview

Sector: Healthcare | Industry: Healthcare Plans | Exchange: NYSE (USA) | Market Cap: 7.031m USD | Total Return: 39.2% in 12m

Health Insurance, Software Platform, Reinsurance, Enrollment Services
Total Rating 48
Safety 44
Buy Signal 1.20
Healthcare Plans
Industry Rotation: +20.2
Market Cap: 7.03B
Avg Turnover: 138M
Risk 3d forecast
Volatility68.7%
VaR 5th Pctl10.4%
VaR vs Median-8.61%
Reward TTM
Sharpe Ratio0.77
Rel. Str. IBD90
Rel. Str. Peer Group97.5
Character TTM
Beta1.230
Beta Downside1.064
Hurst Exponent0.528
Drawdowns 3y
Max DD53.39%
CAGR/Max DD0.91
CAGR/Mean DD1.86
EPS (Earnings per Share) EPS (Earnings per Share) of OSCR over the last years for every Quarter: "2021-03": -0.75, "2021-06": -0.35, "2021-09": -1.02, "2021-12": -0.95, "2022-03": -0.36, "2022-06": -0.53, "2022-09": -0.91, "2022-12": -1.05, "2023-03": -0.18, "2023-06": -0.07, "2023-09": -0.29, "2023-12": -0.66, "2024-03": 0.62, "2024-06": 0.2, "2024-09": -0.22, "2024-12": -0.62, "2025-03": 0.92, "2025-06": -0.89, "2025-09": -0.53, "2025-12": -1.24, "2026-03": 2.07,
EPS CAGR: 48.16%
EPS Trend: 31.8%
Last SUE: 4.00
Qual. Beats: 1
Revenue Revenue of OSCR over the last years for every Quarter: 2021-03: 388.694, 2021-06: 549.747, 2021-09: 462.193, 2021-12: 520.327, 2022-03: 1011.076, 2022-06: 1058.335, 2022-09: 1018.513, 2022-12: 1037.66, 2023-03: 1469.685, 2023-06: 1522.124, 2023-09: 1439.991, 2023-12: 1431.632, 2024-03: 2142.839, 2024-06: 2219.341, 2024-09: 2423.482, 2024-12: 2392.436, 2025-03: 3046.263, 2025-06: 2863.945, 2025-09: 2985.984, 2025-12: 2805.235, 2026-03: 4647.194,
Rev. CAGR: 48.37%
Rev. Trend: 96.3%
Last SUE: -1.68
Qual. Beats: -3

Warnings

Choppy

Tailwinds

Leader, Confidence

Description: OSCR Oscar Health

Oscar Health, Inc. (OSCR) is a technology-driven healthcare company providing health insurance plans to individuals, families, and small business groups across the United States. The firm distinguishes itself through its proprietary full-stack technology platform, +Oscar, which facilitates member engagement, provider recommendations, and administrative efficiency for internal operations and third-party payors.

Operating within the Life & Health Insurance sector, the company utilizes a digital-first business model to manage medical loss ratios and streamline the enrollment process for brokers and consumers. Unlike traditional insurers that often rely on legacy infrastructure, Oscar Health integrates reinsurance products and brokerage services into its ecosystem to diversify revenue streams. Investors can further analyze these operational metrics and valuation trends on ValueRay.

The company, headquartered in New York, underwent a corporate rebranding from Mulberry Health Inc. in 2021. Its current service suite includes the Campaign Builder platform, designed to optimize healthcare outcomes through data-driven member interventions.

Headlines to Watch Out For
  • Medical Loss Ratio improvements drive path toward sustainable GAAP net profitability
  • Individual Exchange enrollment growth fuels core health insurance premium revenue expansion
  • Scaling +Oscar technology platform diversifies revenue via high-margin SaaS third-party contracts
  • Federal subsidy shifts and ACA regulatory changes impact market share stability
  • Expansion into the small group market provides critical membership diversification beyond individuals
Piotroski VR‑10 (Strict) 3.5
Net Income: -39.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.30 > 0.02 and ΔFCF/TA 9.74 > 1.0
NWC/Revenue: 4.79% < 20% (prev -3.71%; Δ 8.50% < -1%)
CFO/TA 0.31 > 3% & CFO 2.84b > Net Income -39.4m
Current Ratio: 1.09 > 1.5 & < 3
Outstanding Shares: last quarter (329.8m) vs 12m ago 7.78% < -2%
Gross Margin: 17.39% > 18% (prev 0.57%; Δ 1.68k% > 0.5%)
Asset Turnover: 175.8% > 50% (prev 172.5%; Δ 3.28% > 0%)
Interest Coverage Ratio: -0.59 > 6 (EBITDA TTM 19.2m / Interest Expense TTM 17.0m)
Altman Z'' -0.84
A: 0.07 (Total Current Assets 7.78b - Total Current Liabilities 7.14b) / Total Assets 9.29b
B: -0.28 (Retained Earnings -2.62b / Total Assets 9.29b)
C: -0.00 (EBIT TTM -9.95m / Avg Total Assets 7.57b)
D: -0.34 (Book Value of Equity -2.61b / Total Liabilities 7.62b)
Altman-Z'' Score: -0.84 = CCC
Beneish M -1.72
DSRI: 0.58 (Receivables 587.0m/763.4m, Revenue 13.30b/10.08b)
GMI: 3.28 (GM 17.39% / 57.10%)
AQI: 0.45 (AQ_t 0.15 / AQ_t-1 0.34)
SGI: 1.32 (Revenue 13.30b / 10.08b)
TATA: -0.31 (NI -39.4m - CFO 2.84b) / TA 9.29b)
Beneish M-Score: -1.72 (Cap -4..+1) = CCC
What is the price of OSCR shares? As of May 18, 2026, the stock is trading at USD 23.32 with a total of 8,536,171 shares traded.
Over the past week, the price has changed by +9.43%, over one month by +47.69%, over three months by +74.16% and over the past year by +39.22%.
Is OSCR a buy, sell or hold? Oscar Health has received a consensus analysts rating of 3.29. Therefor, it is recommend to hold OSCR.
  • StrongBuy: 2
  • Buy: 1
  • Hold: 2
  • Sell: 1
  • StrongSell: 1
What are the forecasts/targets for the OSCR price?
Analysts Target Price 20.3 -13%
Oscar Health (OSCR) - Fundamental Data Overview as of 17 May 2026
P/E Forward = 588.2353
P/S = 0.5285
P/B = 3.4054
Revenue TTM = 13.30b USD
EBIT TTM = -9.95m USD
EBITDA TTM = 19.2m USD
Long Term Debt = 430.9m USD (from longTermDebt, last quarter)
 Short Term Debt = unknown (none)
 Debt = 430.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -6.37b USD (recalculated: Debt 430.9m - CCE 6.80b)
Enterprise Value = 661.9m USD (7.03b + Debt 430.9m - CCE 6.80b)
Interest Coverage Ratio = -0.59 (Ebit TTM -9.95m / Interest Expense TTM 17.0m)
EV/FCF = 0.24x (Enterprise Value 661.9m / FCF TTM 2.80b)
 FCF Yield = 422.9% (FCF TTM 2.80b / Enterprise Value 661.9m)
 FCF Margin = 21.04% (FCF TTM 2.80b / Revenue TTM 13.30b)
Net Margin = -0.30% (Net Income TTM -39.4m / Revenue TTM 13.30b)
Gross Margin = 17.39% ((Revenue TTM 13.30b - Cost of Revenue TTM 10.99b) / Revenue TTM)
Gross Margin QoQ = 30.50% (prev 6.60%)
Tobins Q-Ratio = 0.07 (Enterprise Value 661.9m / Total Assets 9.29b)
Interest Expense / Debt = 1.25% (Interest Expense 5.38m / Debt 430.9m)
Taxrate = 2.83% (19.8m / 698.8m)
NOPAT = -9.67m (EBIT -9.95m * (1 - 2.83%)) [loss with tax shield]
Current Ratio = 1.09 (Total Current Assets 7.78b / Total Current Liabilities 7.14b)
Debt / Equity = 0.26 (Debt 430.9m / totalStockholderEquity, last quarter 1.66b)
 Debt / EBITDA = -331.2 (out of range, set to none) (Net Debt -6.37b / EBITDA 19.2m)
 Debt / FCF = -2.28 (Net Debt -6.37b / FCF TTM 2.80b)
Total Stockholder Equity = 1.21b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.52% (Net Income -39.4m / Total Assets 9.29b)
RoE = -3.27% (Net Income TTM -39.4m / Total Stockholder Equity 1.21b)
RoCE = -0.61% (EBIT -9.95m / Capital Employed (Equity 1.21b + L.T.Debt 430.9m))
 RoIC = -0.58% (negative operating profit) (NOPAT -9.67m / Invested Capital 1.67b)
 WACC = 9.78% (E(7.03b)/V(7.46b) * Re(10.31%) + D(430.9m)/V(7.46b) * Rd(1.25%) * (1-Tc(0.03)))
Discount Rate = 10.31% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 33.33 | Cagr: 18.03%
[DCF] Terminal Value 63.01% ; FCFF base≈2.16b ; Y1≈1.42b ; Y5≈647.3m
[DCF] Fair Price = 60.73 (EV 9.78b - Net Debt -6.37b = Equity 16.15b / Shares 265.9m; r=9.78% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 31.77 | EPS CAGR: 48.16% | SUE: 4.0 | # QB: 1
Revenue Correlation: 96.30 | Revenue CAGR: 48.37% | SUE: -1.68 | # QB: -3
EPS current Quarter (2026-06-30): EPS=0.40 | Chg30d=+179.23% | Revisions=+25% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.19 | Chg30d=-154.61% | Revisions=-25% | Analysts=9
EPS current Year (2026-12-31): EPS=0.97 | Chg30d=+54.40% | Revisions=+56% | GrowthEPS=+157.3% | GrowthRev=+60.2%
EPS next Year (2027-12-31): EPS=1.38 | Chg30d=+2.53% | Revisions=+33% | GrowthEPS=+42.6% | GrowthRev=+6.0%
[Analyst] Revisions Ratio: +56%